Convexal subarachnoid haemorrhage in a patient under pembrolizumab-lenvatinib combination therapy

被引:0
|
作者
Simao, Paulo [1 ,2 ]
Almeida, Marco Jose [3 ]
Catela, Joao [4 ]
Matias, Fernando [3 ]
机构
[1] Ctr Hosp & Univ Coimbra EPE, Internal Med, Campus Hosp Univ Coimbra, Coimbra, Portugal
[2] Ctr Hosp & Univ Cova Beira EPE, Internal Med, Covilha, Portugal
[3] Ctr Hosp & Univ Coimbra EPE, Neurol, Campus Hosp & Univ Coimbra, Coimbra, Portugal
[4] Ctr Hosp & Univ Coimbra EPE, Neurosurg, Coimbra, Portugal
关键词
Epilepsy and seizures; Neuroimaging; Non-vascular; Gynecological cancer; Unwanted effects / adverse reactions; CELL LUNG-CANCER; MELANOMA;
D O I
10.1136/bcr-2023-256100
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
A woman in her 60s was brought to the emergency department due to a new-onset seizure. She was drowsy on arrival and unable to provide a clinical history. She had a medical history of advanced endometrial cancer, for which she was under the therapeutic protocol pembrolizumab plus lenvatinib. Laboratorial investigations were unremarkable. The brain CT angiography provided further insight into the case by detecting a bilateral convexal subarachnoid haemorrhage with discrete bilateral opercular vasogenic oedema, without other noticeable structural changes. Cerebrospinal fluid analysis was macroscopically haemorrhagic, but otherwise unremarkable. The brain MRI did not provide additional information. Although considered a rare adverse reaction, cerebral haemorrhage has been described for both pembrolizumab and lenvatinib. We cautiously assumed a probable drug aetiology after a thorough review of potential causes. Following discontinuation of these drugs and under anti-convulsive therapy, the patient remained asymptomatic and was discharged home.
引用
收藏
页数:3
相关论文
共 50 条
  • [31] Symptomatic methemoglobinemia in a patient with metastatic clear cell renal cell carcinoma treated with pembrolizumab and axitinib combination therapy: a case report
    Olsen, T. Anders
    Martini, Dylan J.
    Evans, Sean T.
    Goldman, Jamie M.
    Bilen, Mehmet Asim
    JOURNAL OF MEDICAL CASE REPORTS, 2021, 15 (01)
  • [32] Symptomatic methemoglobinemia in a patient with metastatic clear cell renal cell carcinoma treated with pembrolizumab and axitinib combination therapy: a case report
    T. Anders Olsen
    Dylan J. Martini
    Sean T. Evans
    Jamie M. Goldman
    Mehmet Asim Bilen
    Journal of Medical Case Reports, 15
  • [33] Sustained clinical remission under infliximab/rituximab combination therapy in a patient with granulomatosis with polyangiitis
    Valor-Mendez, Larissa
    Kleyer, Arnd
    Rech, Juergen
    Manger, Bernhard
    Schett, Georg
    AUTOIMMUNITY HIGHLIGHTS, 2021, 12 (01)
  • [34] Clinicopathological characteristics of kidney injury in non-small cell lung cancer patients under combination therapy including pembrolizumab
    Aratani, Sae
    Sugano, Teppei
    Shimizu, Akira
    Seike, Masahiro
    Kashiwagi, Tetsuya
    Gemma, Akihiko
    Sakai, Yukinao
    CEN CASE REPORTS, 2022, 11 (01) : 97 - 104
  • [35] Clinicopathological characteristics of kidney injury in non-small cell lung cancer patients under combination therapy including pembrolizumab
    Sae Aratani
    Teppei Sugano
    Akira Shimizu
    Masahiro Seike
    Tetsuya Kashiwagi
    Akihiko Gemma
    Yukinao Sakai
    CEN Case Reports, 2022, 11 : 97 - 104
  • [36] Osteonecrosis of the jaw in a metastatic lung cancer patient with bone metastases undergoing pembrolizumab plus denosumab combination therapy: Case report and literature review
    Myoken, Yoshinari
    Fujita, Yoshinori
    Kawamoto, Kazuma
    Toratani, Shigeaki
    ORAL ONCOLOGY, 2020, 111
  • [37] First-line Therapy for advanced clear cell Renal Cell Carcinoma An open-label, randomized, Phase III Study for Evaluating the Efficacy and Safety of Pembrolizumab (MK-3475) in combination with Belzutifan (MK-6482) and Lenvatinib (MK-7902) or MK-1308A in combination with Lenvatinib versus Pembrolizumab and Lenvatinib as First-line Treatment in Participants with advanced Clear Cell Renal Cell Carcinoma (ccRCC) (AUO AN 54/21, HIF-012)
    Rexer, Heidrun
    Bedke, Jens
    Busch, Jonas
    AKTUELLE UROLOGIE, 2022, 53 (05) : 400 - 401
  • [38] Lenvatinib plus pembrolizumab combination therapy in patients with radioiodine-refractory (RAIR), progressive differentiated thyroid cancer (DTC): Results of a multicenter phase II international thyroid oncology group trial.
    Haugen, Bryan
    French, Jena
    Worden, Francis P.
    Konda, Bhavana
    Sherman, Eric Jeffrey
    Dadu, Ramona
    Gianoukakis, Andrew G.
    Wolfe, Eric G.
    Foster, Nathan R.
    Bowles, Daniel W.
    Wirth, Lori J.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [39] A case of papillary renal cell carcinoma with para-aortic lymph node metastasis that was completely resectable after treatment with combination therapy comprising lenvatinib and pembrolizumab and robot-assisted radical nephrectomy
    Hosoi, Takayuki
    Yoshioka, Shunsuke
    Hiraguri, Akari
    Kirihana, Yusuke
    Koguchi, Tomoyuki
    Tamaki, Makoto
    Irisawa, Chiharu
    IJU CASE REPORTS, 2025, 8 (02) : 150 - 153
  • [40] Non-Invasive Prevention of Malignant Airway Obstruction in an Elderly Lung Cancer Patient Using Early Chemo Combination With Pembrolizumab Therapy: A Case Study
    Nigi, Akina
    Iwamoto, Keisuke
    Yabana, Tadashi
    Tanaka, Hiroyuki
    Toyoshima, Hirokazu
    RESPIROLOGY CASE REPORTS, 2025, 13 (03):